NOMINATIONS are now open for
the Complementary Healthcare
Council’s (CHC) Annual Industry
Awards.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 31 Jul 12 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Jul 12
CONSUMERS and health professionals are advised that Biogen Australia, in consultation with the Therapeutic Goods Administration (TGA), will withdraw multiple sclerosis therapy Zinbryta (daclizumab) from the Australian market following a review of cases of serious inflammatory brain disorders in Europe (PD 05 Mar).